ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: INFO14-SA

Cure Glomerulonephropathy Network (CureGN)

Session Information

  • Informational Posters - III
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • No subcategory defined


  • Helmuth, Margaret, University of Michigan, Ann Arbor, Michigan, United States
  • Aviles, Diego H., Children's Hospital New Orleans, New Orleans, Louisiana, United States
  • Bartosh, Sharon M., University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Bomback, Andrew S., Columbia University, New York, New York, United States
  • Derebail, Vimal K., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Sethna, Christine B., Northwell Health, New Hyde Park, New York, United States
  • Srivastava, Tarak, Children's Mercy Hospital Kansas, Overland Park, Kansas, United States
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States

Group or Team Name

  • On Behalf of the CureGN Consortium

CureGN is a multi-center, prospective observational cohort study of glomerular disease funded by the NIH-NIDDK. CureGN has enrolled 2,755 participants with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA (immunoglobulin A) vasculitis with nephritis or nephropathy (IgAV-N) from 71 sites internationally since Dec. 2014.

Pediatric and adult patients biopsied within 5 years are eligible to participate. Exclusion criteria include kidney failure at enrollment, diabetes at biopsy, and glomerular disease attributed to a secondary cause. Sociodemographic, clinical, pathologic, and patient reported data collection is enriched by a diverse biorepository and digital pathology repository (DPR). Renal and non-renal outcomes are collected. Participant characteristics with median 5.1 year follow up are shown (Table 1).

CureGN supports multi-dimensional translational research by combining clinical phenotype, pathology, and outcome data with insight derived from longitudinally collected DNA, RNA, blood, and urine specimens. To date, whole genome sequencing and RNA sequencing has been performed on 2,009 and 2,128 patients, respectively. The DPR can provide annotated images or quantitative scoring data from kidney biopsies for investigators, and currently stores images from 1,253 patient biopsies, 1,045 of which are scored. An online data-sharing tool (tranSMART) is available to researchers for hypothesis generation.

The study objectives support a variety of ways to identify mechanistically distinct subgroups, discover/validate biomarkers, delineate disease-specific treatment targets, and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular diseases. Patient input into the study is integrated via a patient advisory panel. The Career Development Group provides peer mentoring for young investigators interested in glomerular disease. The consortium invites ancillary study proposals from Network and extramural investigators.


  • Funding for the CureGN consortium is provided by U24DK100845 (formerly UM1DK100845), U01DK100846 (formerly UM1DK100846), U01DK100876 (formerly UM1DK100876), U01DK100866 (formerly UM1DK100866), and U01DK100867 (formerly UM1DK100867) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International.